Bill Cheliak, Chairman

Dr. Cheliak is the CEO of Panag Pharma, a Canadian biotech company focused on the development of novel cannabinoid-based formulations for the treatment of pain and inflammation. Dr. Cheliak has over 20 years of business experience in a wide variety of biotechnology fields, including vaccines, human genetics, oncology, neurology and anti-infective drug development and CRO services. In addition to having held executive positions in the public sector, he has extensive deal-making experience within the pharmaceutical industry, academic institutions and research hospitals including securing financing with both big and small pharma. He currently serves as a Director of Solarvest (SVS) and is Vice Chair of the Government of Canada’s Networks Centres of Excellence (NCE) Standing Selection Committee and Chair of the NCE Monitoring Committee providing advice and recommendations to the Government of Canada on funding of large national science and infrastructure initiatives. Dr. Cheliak has a Ph.D. in Genetics from the University of Alberta.

Guy Chamberland, Director

Dr. Guy Chamberland, M.Sc., Ph.D., Master Herbalist, is a drug development specialist with 25 years experience in the pharmaceutical industry. Having obtained a Master’s of Science and Doctorate (PhD) degree in biomedical sciences, he has developed an expertise in drug safety and regulatory affairs while working in the pharmaceutical and biotechnology industries. He has specific expertise in the development of drug-device combination products, biologics, and botanical medicines.

Dr. Chamberland has served as Tetra Bio-Pharma’s Chief Executive Officer and Chief Regulatory Officer since October 15, 2018. He is responsible for the transformation of the biotechnology company into a pharmaceutical firm that discovers, develops and commercializes cannabinoid-based pharmaceuticals. The mandate began with a company of less than 10 employees and today has over 50 employees specialized in regulatory affairs, clinical research, manufacturing compliance, clinical trial product manufacturing, clinical operations and research and development. Dr. Chamberland oversees the scientific and regulatory requirements for drug and medical device approval (i.e., vaporizers) and strategic planning for corporate development.

Dr. Chamberland has become a thought leader in botanical medicine, publishing, lecturing and delivering continuing education workshops to health professionals on the use of plants for the treatment of pain, anxiety, insomnia, and wound healing. He is a Professor of Botanical Medicine and Principles of Clinical Research at the École d’Enseignement Supérieur de Naturopathie du Québec (EESNQ) and the French language equivalent of the Canadian College of Naturopathic Medicine (CCNNM). He earned a diploma in Proficiency in Herbal Prescription from the Australian College of Phytotherapy, and Certified Herbalist and Master Herbalist diplomas from the Dominion College of Canada. Dr. Chamberland received a B.Sc. in Agriculture form McGill University, an M.Sc. in Veterinary Anatomy and Physiology and a Ph.D. in Biomedical Sciences (toxicology) from the University of Montreal.

Dr. Chamberland is a pioneer in drug-device combination products. He developed and executed the regulatory strategy for two novel products and obtained marketing approval. In 2002, he was invited by the FDA to present at the FDA Public Hearing to regulate combination products. He spent 7-years as a member of the Scientific Advisory Committee of a Venture Capital fund and 6-years on a Health Canada Expert Committee. He was also employed by the Victhom Laboratory; Angiogene Inc.; CATO Research Ltd; and MDS Pharma, respectively.

Carl Merton , Director

Mr. Merton has over 20 years of financial and business experience, including 10 years as CFO for public companies involved in the capital markets. Following 12 years with Ernst & Young and KPMG, he transitioned from the audit stream into financial advisory work, as a Business Valuator, Forensic Accountant and Corporate Finance specialist. After leaving KPMG, Mr. Merton joined Atlas Tube Inc., as Vice-President, Special Projects. Since assisting in the sale of Atlas Tube, Mr. Merton became the CFO of Reko International Group Inc. In December 2014, Mr. Merton was elected by shareholders as a member of the inaugural Board of Directors of Aphria Inc. Approximately one year later, Mr. Merton resigned as a member of the Board and joined Aphria as its CFO. In this role, Mr. Merton is responsible for communication with all stakeholders and is a member of the executive management team responsible for the strategic direction of Aphria, as well as leading all acquisition discussions, budgeting, financing, financial reporting and internal controls. Mr. Merton is a Chartered Professional Accountant, a Chartered Accountant and is a Fellow of the Canadian Institute of Chartered Business Valuators (the “CICBV”).

Brent Norton, Director

Dr. Brent Norton holds his medical doctorate degree from McGill University, an MBA from Ivey Business School at Western University and was granted the ICD.D designation by the Institute of Corporate Directors following the completion of the Directors Education Program at the Rotman School of Business in Toronto. With over 25 years of experience in the life sciences industry, Dr. Norton has used his cross-functional knowledge to develop strategy, raise capital and build important relationships in the academic and business community. Operationally, he has built R&D and commercial operations, led transactions with AstraZeneca, Eli Lilly, L’Oreal, Parke Davis/Pfizer and others, and taken products through the FDA to global out-licensing with Johnson & Johnson. His contributions to five companies have allowed early investors the opportunity to crystallize investment gains of over $2.5B. Brent is currently a Venture Partner with Lumira Ventures and has recently been appointed as a member of the prestigious Association of Faculties of Medicine of Canada.

Dale Weil, Director

Dale Weil brings close to 35 years of business development experience, much of which was acquired while working at McKesson Canada, a diversified healthcare company and the largest pharmaceutical distributor in the country. At McKesson Canada, Ms. Weil held various leadership positions, most recently as Senior Advisor to the President. Ms. Weil holds a Bachelor's degree in Marine Biology and a Master's degree in Business Administration, both from McGill University. Additionally, Dale received the ICD.D designation from the Institute of Corporate Directors. The ICD.D designation represents a lifelong commitment to excellence in the boardroom, a desire to stay current, and to be a more effective director. In January 2020, Dale was appointed as the Executive Director of the West Island Palliative Care Centre, an initiative that she has been involved with since 2010.